Loading...
A cross-sectional analysis of treatment patterns in small-cell lung cancer in five European countries
Reguart, N. Pérol, M. Cortinovis, D. Puntis, S. Öhrling, K. Archangelidi, O. Louie, K. S. Blackhall, Fiona Sebastian, M.
Reguart, N.
Pérol, M.
Cortinovis, D.
Puntis, S.
Öhrling, K.
Archangelidi, O.
Louie, K. S.
Blackhall, Fiona
Sebastian, M.
Citations
Altmetric:
Abstract
Aim: To investigate changes in treatment patterns in extensive-stage small-cell lung cancer (ES-SCLC) in France, Germany, Italy, Spain and the UK (EU5) between 2018 and 2021. Methods: Cross-sectional data from an oncology database were analyzed retrospectively. Results: Of 5832 eligible patients, 88.4% had stage IV disease at diagnosis. Among patients receiving first-line treatment, 91.8% (1079 /1176) received the platinum-etoposide (PE) combination in 2018 which decreased to 42.3% (509/1203) by 2021. Usage of the PE-atezolizumab combination increased from 0 to 41.2% during the same timeframe. Topotecan monotherapy remained the most widely used second-line treatment regardless of patients' platinum sensitivity. Conclusion: The first-line standard of care for ES-SCLC has evolved in EU5 with the PE-atezolizumab/durvalumab combination gradually superseding PE usage.
Description
Date
2023
Publisher
Collections
Files
Keywords
Type
Article
Citation
Reguart N, Pérol M, Cortinovis D, Puntis S, Öhrling K, Archangelidi O, et al. A cross-sectional analysis of treatment patterns in small-cell lung cancer in five European countries. Future oncology (London, England). 2023 Nov 30. PubMed PMID: 38031886. Epub 2023/11/30. eng.